User login
A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.
Topic Highlights
• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment
• 3-Year Experience With Imiquimod in Vulvar Warts
• Placebo-Controlled Trial in External Anogenital Warts
• Phase III Trials of Imiquimod in Actinic Keratosis
• Observational Long-Term Study of Imiquimod in Actinic Keratosis
• Immune Response Modifier Mechanism of Action
A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.
Topic Highlights
• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment
• 3-Year Experience With Imiquimod in Vulvar Warts
• Placebo-Controlled Trial in External Anogenital Warts
• Phase III Trials of Imiquimod in Actinic Keratosis
• Observational Long-Term Study of Imiquimod in Actinic Keratosis
• Immune Response Modifier Mechanism of Action
A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.
Topic Highlights
• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment
• 3-Year Experience With Imiquimod in Vulvar Warts
• Placebo-Controlled Trial in External Anogenital Warts
• Phase III Trials of Imiquimod in Actinic Keratosis
• Observational Long-Term Study of Imiquimod in Actinic Keratosis
• Immune Response Modifier Mechanism of Action
